Exosome miR-552 Promotes Laryngocarcinoma Cells Malignant Progression via the PTEN/TOB1 Axis.

IF 2.9 4区医学 Q2 PHARMACOLOGY & PHARMACY Pharmacology Pub Date : 2023-01-01 DOI:10.1159/000529887

Lisha Liu, Qiaojing Jia, Jianxing Wang, Haizhong Zhang, Zhanwei Jia, Chunguang Shan

{"title":"Exosome miR-552 Promotes Laryngocarcinoma Cells Malignant Progression via the PTEN/TOB1 Axis.","authors":"Lisha Liu, Qiaojing Jia, Jianxing Wang, Haizhong Zhang, Zhanwei Jia, Chunguang Shan","doi":"10.1159/000529887","DOIUrl":null,"url":null,"abstract":"Introduction: Tumor exosome-derived miRNAs play important roles in the human laryngocarcinoma. However, it is still unknown if exosome miR-552 is involved in the laryngocarcinoma. The aim of the current study was to explore exosome miR-552's role in laryngocarcinoma and its underlying mechanisms.Methods: Hep-2 exosome was characterized by transmission electron microscopy and nanoparticle tracking technology. CCK-8 was used to determine cell viability, and a xenograft animal model was used to determine the tumorigenicity. qPCR and Western blotting were used to measure the changes in target biomarkers. Luciferase reporter assay was used to evaluate the interactions between miR-552 and PTEN. miRNA sequencing was used to check the changes in miRNA profiles.Results: miR-552 was upregulated in the laryngocarcinoma patients and was positively correlated to the cell proliferation and tumor growth. PTEN was identified as a direct target of miR-552. Hep-2 exosome is featured by high expression of miR-552 and treatment of Hep-2 exosome enhanced cell proliferation and tumorigenicity. The underlying mechanisms revealed that treatment of exosomes enhanced the malignant transformation of recipient cells in part by regulating epithelial-mesenchymal transition.Conclusion: Exosome miR-552 promotes laryngocarcinoma cells' malignant progression in part by the regulation of the PTEN/TOB1 axis.","PeriodicalId":20209,"journal":{"name":"Pharmacology","volume":"108 4","pages":"321-330"},"PeriodicalIF":2.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000529887","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction: Tumor exosome-derived miRNAs play important roles in the human laryngocarcinoma. However, it is still unknown if exosome miR-552 is involved in the laryngocarcinoma. The aim of the current study was to explore exosome miR-552's role in laryngocarcinoma and its underlying mechanisms.

Methods: Hep-2 exosome was characterized by transmission electron microscopy and nanoparticle tracking technology. CCK-8 was used to determine cell viability, and a xenograft animal model was used to determine the tumorigenicity. qPCR and Western blotting were used to measure the changes in target biomarkers. Luciferase reporter assay was used to evaluate the interactions between miR-552 and PTEN. miRNA sequencing was used to check the changes in miRNA profiles.

Results: miR-552 was upregulated in the laryngocarcinoma patients and was positively correlated to the cell proliferation and tumor growth. PTEN was identified as a direct target of miR-552. Hep-2 exosome is featured by high expression of miR-552 and treatment of Hep-2 exosome enhanced cell proliferation and tumorigenicity. The underlying mechanisms revealed that treatment of exosomes enhanced the malignant transformation of recipient cells in part by regulating epithelial-mesenchymal transition.

Conclusion: Exosome miR-552 promotes laryngocarcinoma cells' malignant progression in part by the regulation of the PTEN/TOB1 axis.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

外泌体miR-552通过PTEN/TOB1轴促进喉癌细胞恶性进展

肿瘤外泌体来源的mirna在人喉癌中起重要作用。然而，外泌体miR-552是否参与喉癌尚不清楚。本研究的目的是探讨外泌体miR-552在喉癌中的作用及其潜在机制。方法:采用透射电镜和纳米颗粒跟踪技术对Hep-2外泌体进行表征。采用CCK-8测定细胞活力，采用异种移植动物模型测定致瘤性。采用qPCR和Western blotting检测目标生物标志物的变化。荧光素酶报告试验用于评估miR-552与PTEN之间的相互作用。使用miRNA测序来检查miRNA谱的变化。结果:miR-552在喉癌患者中表达上调，与细胞增殖和肿瘤生长呈正相关。PTEN被确定为miR-552的直接靶点。Hep-2外泌体的特点是miR-552高表达，处理Hep-2外泌体可增强细胞增殖和致瘤性。潜在的机制表明，外泌体的治疗在一定程度上通过调节上皮-间质转化来增强受体细胞的恶性转化。结论:外泌体miR-552部分通过调控PTEN/TOB1轴促进喉癌细胞的恶性进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pharmacology 医学-药学

CiteScore

5.60

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Pharmacology'' is an international forum to present and discuss current perspectives in drug research. The journal communicates research in basic and clinical pharmacology and related fields. It covers biochemical pharmacology, molecular pharmacology, immunopharmacology, drug metabolism, pharmacogenetics, analytical toxicology, neuropsychopharmacology, pharmacokinetics and clinical pharmacology. In addition to original papers and short communications of investigative findings and pharmacological profiles the journal contains reviews, comments and perspective notes; research communications of novel therapeutic agents are encouraged.